États-Unis · Plateformes & données · The Motley Fool

CME vs. Nu: Which Financial Stock Is a Better Buy for 2027?

Publié par The Motley Fool · États-Unis il y a 1 h

CME boasts a 62% net margin and fortress balance sheet, while Nu's 43% revenue growth signals emerging-market momentum, but their risk profiles diverge sharply.

Lire l'article complet sur The Motley Fool Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.fool.com)

CME vs. Nu: Which Financial Stock Is a Better Buy for 2027?

À lire aussi

Treasury yields fall after Democrats win House and Senate majorities

CVS Health plans to split in two. Here’s what is driving the massive healthcare breakup.

Best Stocks Under $5

CS Disco LLC earnings missed by $0.06, revenue topped estimates

Market News

HC Wainwright & Co. upgrades Inovio Pharmaceuticals to Buy from Neutral, sets price target at $5

CME vs. Nu: Which Financial Stock Is a Better Buy for 2027?

Partager

À lire aussi

Treasury yields fall after Democrats win House and Senate majorities

CVS Health plans to split in two. Here’s what is driving the massive healthcare breakup.

Best Stocks Under $5

CS Disco LLC earnings missed by $0.06, revenue topped estimates

Market News

HC Wainwright & Co. upgrades Inovio Pharmaceuticals to Buy from Neutral, sets price target at $5